AKR1C enzymes sustain therapy resistance in pediatric T-ALL

ABSTRACT: Although intensification of chemotherapy approaches considerably increased the outcome of pediatric T-cell Acute Lymphoblastic Leukemia (T-ALL) patients, a subgroup of them still experience treatment failure and relapse. In this context, we hypothesized that the Nrf2 signalling and its downstream effectors could be involved in sustain therapy resistance in T-ALL, as previously reported in other cancers. Indeed, in this study we identified the Aldo-Keto Reductase (AKR) enzymes AKR1C1-3, as over-expressed in T-ALL samples from therapy-resistant patients, demonstrating their fundamental role in the control of the response to vincristine (VCR) treatment. In particular, we evidence that the modulation of AKR1C1-3 gene expression and activity is sufficient to strongly affect the sensitivity of T-ALL cell lines and primary cells to VCR treatment, but not to daunorubicin, cytarabine or L-asparaginase. Moreover, we found a correlation between the degree of VCR response and the amount of AKR1Cs expression in patient-derived T-ALL xenografts. Interestingly, we show that daunorubicin and cytarabine are able to induce the over-activation of AKR1C enzymes, thus establishing a potential resistance loop generated by the combination of these drugs during T-ALL treatment. In this study, we demonstrate a clear involvement of AKR1C enzymes in controlling the response to chemotherapics in T-ALL, suggesting the possibility of considering AKR1Cs as reliable targets for the setup of novel combination treatments for T-ALL patients who do not respond to therapy

ORGANISM(S): Homo sapiens

PROVIDER: GSE87865 | GEO | 2017/09/30

SECONDARY ACCESSION(S): PRJNA347921

REPOSITORIES: GEO